Unraveling the role of glutamine metabolism in cancer: from cell death mechanisms to tumor microenvironment modulation Authors: Xintong Peng, Shuang Liu, Yongguang Tao Published: 2026 ABSTRACT AbstractGlutamine, the most abundant amino acid in human serum, serves not only as a key nutrient for maintaining normal cellular biological functions but also as an essential metabolic substrate for the proliferation and survival of tumor cells. Tumor cells exhibit a pronounced characteristic of “glutamine addiction” through metabolic reprogramming. This trait endows tumor cells with the dual capacity to exhibit both adaptability and vulnerability when confronted with regulated cell death (RCD) under metabolic stress, thereby opening up potential avenues for cancer therapy. This paper systematically reviews the biological functions of glutamine metabolism, delves into its relationships with various types of regulated cell death, elucidates its role in immune microenvironment, and summarizes the current application progress of anti-tumor drugs targeting glutamine metabolism.Keywords: Glutamine metabolism, Regulated cell death, Tumor microenvironment, Glutamine metabolism-targeted drugs Introduction Glutamine, classified as both a nonessential amino acid (NEAA) and a conditionally essential amino acid, represents the most abundant amino acid in the circulatory system, accounting for over 20% of the total amino acid pool in blood, with concentrations reaching up to 40% in muscles [1, 2]. Glutamine plays multiple pivotal roles in metabolism: acting as the principal donor of reduced nitrogen for the biosynthesis of nitrogen-containing compounds such as nucleotides, glucosamines, and nonessential amino acids, replenishing intermediates of the tricarboxylic acid (TCA) cycle, facilitating the production of glutathione, and providing carbon sources for lipid synthesis through reductive carboxylation [3, 4]. These core functions reveal that glutamine metabolism lies at the crossroads of carbon and nitrogen metabolism, functioning as the central hub of the cellular metabolic network. Glutamine dependence is regarded as a metabolic hallmark of proliferating cells. When exposed to catabolic stress conditions, including post-surgical states, traumatic injuries, or sepsis, cells within the kidneys, gastrointestinal tract, and immune compartments exhibit a marked surge in glutamine consumption. This heightened uptake subsequently results in a strong dependence of these cells on glutamine [5]. Similarly, tumor cells are known for their Warburg effect, which leads them to mainly depend on aerobic glycolysis for energy acquisition. However, in order to sustain normal mitochondrial functions, these cells often turn to glutamine as a major energy supplier. Tumor cells use glutamine to replenish the intermediates in the TCA cycle via anaplerotic reactions, a phenomenon referred to as “glutamine addiction” [5, 6]. Moreover, glutamine metabolism and its closely related metabolic networks, including glutamine transporters, glutaminases, aminotransferases, and redox balance, are of vital importance for the survival and metabolic reprogramming of tumor cells. Cell death is a pivotal process for maintaining physiological homeostasis within the organism, responsible for clearing damaged cells and defending against pathogen invasion. Based on different morphological changes and triggering mechanisms, cell death can be classified into apoptosis, necrosis, autophagy, ferroptosis, pyroptosis, cuproptosis, and disulfidptosis. In contrast to accidental cell death, regulated cell death is under precise control mediated by genes and signaling pathways. Nevertheless, tumor cells frequently exhibit resistance to cell death, which subsequently gives rise to drug resistance, tumor recurrence, metastasis, and immune evasion [7]. Consequently, the induction of regulated cell death in tumor cells has become an important tumor treatment strategy. Numerous studies have revealed that there’s a complicated link between cell death and metabolism in cancer cells. A deficiency in metabolites can trigger a cascade of functional disorders and even directly cell death [8]. Since metabolic stress is an essential factor in causing cell death, the relationship between cell death and metabolism has been getting more and more attention in recent years. Additionally, the tumor microenvironment (TME) is crucial for tumor initiation and progression. Some immunogenic cell death can influence tumor progression by activating tumor immune responses [9]. One thing that’s getting a lot of attention is the complex glutamine competition between immune cells and tumor cells. Hence, a thorough comprehension of the functional role of glutamine metabolism within the TME is of critical importance for the identification of novel therapeutic targets and the enhancement of the therapeutic efficacy of tumor immunotherapy. This review systematically demonstrates the impact of glutamine metabolism on different types of cell death, elucidates the intricate relationship between metabolic alterations and cell death within the TME, and summarize the current research progress and clinical treatment outcomes of anti-tumor drugs targeting glutamine metabolism. This review can provide profound insights and clear directions for future cancer therapeutic strategies targeting glutamine metabolism. Basic biological functions of glutamine This section provides a brief overview of the central role of glutamine in cellular metabolism. Leveraging key metabolic hubs such as α-ketoglutarate (α-KG), glutathione (GSH), and ATP, glutamine performs multiple functions in cellular energy supply, providing the biosynthetic precursor, regulation of redox status, and epigenetic modifications (Fig. 1). Furthermore, we discuss the critical role of glutamine in tumor metabolic reprogramming. Basic biological functions of glutamine. Glutamine is transported into mammalian cells via membrane transporters (e.g., SLC1A5, SLC6A14, SLC38A2/A5), and the SLC1A5 variant facilitates glutamine uptake into mitochondria. Within mitochondria, glutaminase (GLS) converts glutamine to glutamate, which is further metabolized to α-KG by glutamate dehydrogenase (GLUD) or transaminases (glutamic-oxaloacetic transaminase 2 and glutamic-pyruvic transaminase 2). In the cytoplasm, phosphoserine aminotransferase 1(PSAT1) catalyzes the conversion of glutamate to α-KG. The α-KG generated serves as a critical intermediate for energy production through the TCA cycle and participates in epigenetic regulation via DNA and histone demethylation. Additionally, glutamine contributes to the biosynthesis of GSH, nucleotides, and amino acids Role of glutamine in energy generation Multiple transport proteins are responsible for uptake of glutamine from the extracellular environment into the cell, including (1) SLC1A5 (Solute carrier family 1 member 5; also known as ASCT2); (2) SLC38A2 and SLC38A5 (Solute carrier family 38 member 2 & 5), among which SLC38A5 is considered the main carrier for glutamine uptake; (3) SLC6A14 (Solute carrier family 6 member 14). Meanwhile, SLC7A11 (Solute carrier family 7 member 11) forms a heterodimeric antiport carrier with SLC3A2 (Solute carrier family 3 member 2), mediating the efflux of glutamine and the influx of leucine [10]. Subsequently, the SLC1A5 variant transports glutamine into the mitochondrial matrix [11]. Here, glutamine is first converted into glutamate (Glu) by GLS, which is the first and rate—limiting step of glutamine catabolism. In a reversible reaction, glutamine synthetase (GS) can catalyze the linkage of glutamate and ammonia to produce glutamine [12]. Then, glutamate is further converted into α-KG through different pathways by GLUD or by transaminases, including glutamic-oxaloacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT), and PSAT1 [13]. This conversion process is accompanied by the release of ammonia, aspartate, alanine, and serine, respectively. Ultimately, α-KG enters the tricarboxylic acid (TCA) cycle, engaging in a series of reactions to generate NADH and FADH2. These molecules are then used to produce ATP, thus providing energy for cellular functions. Moreover, citrate, a TCA cycle intermediate, is transported from mitochondria to cytoplasm and converted to acetyl-CoA, a key precursor of lipid synthesis. Thus, glutamine is involved in lipid metabolism via this route [14]. Glutamine: a nitrogen source for amino acid and nucleotide biosynthesis Glutamine is the essential nitrogen source for the synthesis of non-essential amino acids and nucleotides. It can be directly converted to glutamate, which is pivotal in the non-essential amino acids metabolism, facilitating the synthesis of aspartate, alanine, proline, and serine. These amino acids are further used to synthesize others like arginine, cysteine, and glycine [13]. In detail, glutamine-to-glutamate conversion initiates various amino acid synthesis. GOT then converts oxaloacetate (OAA) to aspartate. Meanwhile, both cytoplasmic Glutamic Pyruvate Transaminase 1 (GPT1) and mitochondrial Glutamic Pyruvate Transaminase 2 (GPT2) catalyze the conversion of pyruvate to alanine. PSAT1 generates 3-phosphoserine by a transamination reaction, which phosphoserine phosphatase (PSPH) hydrolyzes to serine, and hydroxymethyltransferase (SHMT) further converts serine to glycine [15–17]. Interestingly, an elevation in the availablility of asparagine has been shown to upregulate the expression of glutamine synthetase, thereby reversely stimulating the biosynthesis of glutamine [18]. Overall, glutamine is a key source for synthesizing amino acids. Additionally, the γ-nitrogen of glutamine can be utilized for the de novo synthesis of pyrimidines and purines, and its bioavailability is closely linked to this process [19]. During purine synthesis, two glutamine molecules are first utilized to produce inosine monophosphate (IMP), which serves as a precursor for adenosine monophosphate (AMP) and guanosine monophosphate (GMP) biosynthesis [20]. In pyrimidine biosynthesis, the nitrogen derived from glutamine condenses with bicarbonate to form carbamoyl phosphate, thereby leading to the production of uridine triphosphate (UTP) [21]. Next, UTP undergoes catalysis by CTP synthetase (CTPS), accompanied by the consumption of one glutamine molecule, leading to the production of cytidine triphosphate (CTP) [22]. Furthermore, glutamine also supports nucleotide synthesis through other pathways; for instance, aspartate derived from glutamine participates in the biosynthesis of both pyrimidines and purines. In conclusion, glutamine plays a pivotal and indispensable role in the synthesis of biological macromolecules. Role of glutamine metabolism in redox homeostasis Glutamine metabolism plays a crucial role in the cellular antioxidant defense system, primarily by regulating the generation of the antioxidant glutathione (GSH) and thereby supporting cellular antioxidant capacity. Glutathione (GSH) is a tripeptide composed of glutamate, glycine, and cysteine. The glutamate and cysteine derived from glutamine are linked in an ATP-dependent manner via glutamate-cysteine ligase (GCL) [23]. Then, glutathione synthetase (GSS) adds glycine to the γ-glutamate-cysteine, ultimately generating GSH, which scavenges intracellular reactive oxygen species (ROS) [24]. During GSH biosynthesis, intracellular glutamate and glycine are usually sufficient, whereas cysteine is the least abundant. Therefore, glutamine also assists GSH synthesis by facilitating the glutamate efflux and cystine uptake via SLC7A11. Notably, the cystine taken up by SLC7A11 is rapidly reduced to cysteine in cells, underscoring the intimate linkage between SLC7A1- mediated glutathione biosynthesis and glutamine metabolism [25]. Besides being indispensable for GSH synthesis, glutamine also exerts a profound influence on intracellular redox status by boosting NADPH production. In proliferating cells, NADPH contributes to converting oxidized glutathione (GSSG) and thioredoxins to their reduced forms. In solid tumors with limited glucose availability, tumor cells rely on glutamine to generate NADPH via malic enzyme 1 (ME1), crucial for sustaining the tumor’s redox balance [26, 27]. Besides, GOT1 is involved in the regulation of redox homeostasis. For instance, in pancreatic ductal adenocarcinoma (PDAC), GOT1 maintains the NADPH/NADP+ ratio and glutathione levels through the malate-aspartate shuttle [16, 28]. On the other hand, NADH reductive stress in tumor metabolic reprogramming drives reductive glutamine metabolism, manifested as the conversion of α-KG to L-2-hydroxyglutarate (L-2HG) or citrate via IDH-mediated reductive carboxylation [29]. Using mitochondrial uncouplers can redirect glutamine-derived carbon into the oxidative TCA cycle, increasing the NAD⁺/NADH ratio and restoring normal tumor differentiation [30, 31]. In summary, glutamine not only provides five carbon atoms for glutathione synthesis but also elevates intracellular glutathione levels by maintaining the NADPH/NADP⁺ ratio and preventing the efflux of GSSG. Therefore, glutamine is recognized as the primary amino acid responsible for regulating cellular glutathione homeostasis [19, 32]. Role of glutamine metabolism in epigenetic modification Metabolites produced during metabolic processes can act as substrates to engage in chromatin modification, thereby giving rise to a complex interplay between metabolism and epigenetics [33]. Numerous epigenetic modifications are regulated by glutamine-derived metabolites, particularly α-KG, which is closely associated with histone and DNA methylation. In fact, α-KG functions as a substrate both for Jumonji C domain-containing (JMJD) histone demethylases and for the DNA demethylase of ten-eleven-translocation (TET) family. In various solid tumors, glutamine is deficient compared to other amino acids. Glutamine depletion leads to a decrease in α-KG levels, which in turn reduces the activity of JMJD histone demethylases, resulting in hypermethylation of histone H3K27 and ultimately causing cancer cell dedifferentiation [34, 35]. Similarly, TET2 deficiency can induce genomic hypermethylation, affecting the transcriptional activity of both pro-oncogenes and tumor suppressor genes [36]. Additionally, knocking out NLRP3 in mice increases glutamine and promotes glutamate metabolism, modulates the intracellular epigenetic landscape, and suppresses the progression of Alzheimer’s disease [37]. Moreover, glutamine metabolism-driven epigenetic alterations also exist in immune cells. In macrophages, the activation of CD40 initiates fatty acid oxidation and glutamine metabolism. These metabolic changes then induce ATP citrate lyase-dependent epigenetic reprogramming, leading to the upregulation of pro-inflammatory genes and a significant enhancement of the anti-tumor phenotype [38]. In T cells, the glutamine metabolite α-KG can regulate T cell differentiation by altering chromatin accessibility, providing crucial insights for targeting GLS to enhance anti-tumor immune efficacy [39]. Additionally, glutamine enable facilitate the differentiation of AtM B (AtM B cells) cells through epigenetically regulating the expression of T-bet and BATF genes and activating the mTORC1 signaling pathway [40]. Thus, this creates an immunosuppressive microenvironment that accelerates tumor progression. Moreover, α-KG derived from glutamine catabolism is a key factor in promoting M2 macrophage polarization, and α-KG also exerts an influence on the metabolic reprogramming of M2 macrophages through Jmjd3 [41]. In addition, another glutamine metabolite, GSH, can inhibit the activity of S-adenosylmethionine synthetase (MAT1A), which is a key enzyme for the synthesis of S-adenosylmethionine (SAM) [42]. Recent studies have demonstrated that histone H3 is susceptible to S-glutathionylation at the Cyc110 site, leading to alterations in nucleosome stability and chromatin structure, which are associated with oxidative stress and inflammation-related diseases [43]. S-glutathionylation is a specific type of post-translational modification, in which GSH is bound to thiol group (-SH) on the cysteine residues of proteins to form mixed disulfides (Protein-SSG). This biological process is intricately associated with redox-dysregulated diseases, tumor progression, and chemotherapy resistance [44, 45]. The intimate connection between glutamine levels and epigenetic regulation has profound implications for cancer therapeutics. For example, glutamine depletion has been shown to trigger hypermethylation of histones in V600EBRAF melanoma cells, altering the gene expression profile, ultimately conferring resistance to BRAF inhibitor therapy [46]. Thus, glutamine plays a vital role in genomic methylation and protein post-translational modification, and functions as a nexus that bridges amino acid metabolism to various epigenetic changes. Glutamine metabolism and tumor metabolic reprogramming Metabolic reprogramming is a hallmark of tumor progression [47]. Beyond glucose, glutamine is vital for tumor cell growth, replenishing the TCA cycle with intermediates, including non-essential amino acids, ribose, citrate, and glycerol. This compensates for the reduced oxidative phosphorylation in cancer cells resulting from the Warburg effect [48]. Notably, glutamine consumption is markedly elevated across various cancer types, such as breast cancer, melanoma, lung cancer, and prostate cancer [49–52]. Hence, glutamine can be used as a metabolic biomarker for tumor diagnosis. N-acetyl-aspartyl-glutamate (NAAG) serves as a glutamine reservoir in tumor cells, enabling tumor cells to store this crucial metabolite under glutamine deficiency [53]. Glutamine uptake rises in cells with activated MYC and KRAS, with MYC strongly associated with the upregulation of glutamine metabolism in malignant cells. MYC regulates the expression of glutamine transporters and GLS, leading to glutamine dependency in transformed cells [54]. Furthermore, by modulating the expression of GLS and GS, MYC can promote an anti-estrogen resistance phenotype in breast cancer cells [55]. In hematological malignancies, glutamine dependency is a key vulnerability in acute leukemia (AML). IGF2BP2 positively regulates glutamine pathway targets (eg., MYC, GPT2, SLC1A5) in an m6A-dependent way, promoting AML and leukemia stem cell self-renewal. Leukemia stem cells rely on oxidative phosphorylation for energy. Besides, STAT3 regulates AML-specific expression of MYC, which controls SLC1A5 transcription, promoting glutamine uptake and leukemia stem cell survival [56]. Moreover, enzymes in glutamine metabolism play crucial regulatory roles in tumor metabolic reprogramming. For instance, GLS is frequently overexpressed in multiple cancers and linked to poor prognosis, promoting rapid tumor proliferation, cell survival, invasion, and immune evasion [57, 58]. During tumorigenesis and tumor progression, GLS1 activity is linked to the expression of various transcription factors and proteins, including c-MYC, HIF-1α, NF-κB, Rb, mTORC, Rho GTPases, and Nrf2 [58–63]. Consequently, targeting GLS represents a promising therapeutic strategy for tumors with glutamine-dependent phenotypes. In addition, transaminases GPT and GOT also play essential roles in tumor energy metabolism and have been extensively investigated. GPT2 has been shown to contribute critically to tumorigenesis in breast cancer and lung adenocarcinoma [64, 65]. Besides, GOT supports tumor development by supplying aspartate in the cytoplasm, GOT2 promotes hepatocellular carcinoma (HCC) progression via glutamine metabolic reprogramming, suggesting its potential as a therapeutic and diagnostic target in HCC. Mechanistically, silencing GOT2 enhances glutaminolysis, nucleotide synthesis, and GSH production through metabolic reprogramming, which subsequently activates the PI3K/AKT/mTOR pathway and facilitates HCC progression [66]. In nucleotide metabolism, proliferating cells drive nucleotide biosynthesis by coordinating growth factor signals with glutamine utilization. In pancreatic cancer cells, oncogenic KRAS sustains nucleotide pools through a MAPK-dependent signaling pathway, leading to upregulation of MYC. MEK inhibitor reduces glutamine-derived nitrogen incorporation in purine nucleotides [67]. Mutant KRAS not only promotes glutamine-driven nucleotide metabolism but also enhances dependence on transaminases by downregulating GLUD expression, while concurrently driving NADPH production and GSH regeneration [26]. SIRT4 an NAD-dependent mitochondrial enzyme, regulates glutamine metabolism by downregulating GLUD activity, playing a crucial role in regulating glutamine metabolism [68]. Loss of SIRT4 in tumor cells increases glutamine-dependent proliferation and genomic instability, promoting malignancy. Moreover, mTORC1 can activate GLUD to promote glutamine anaplerosis by inhibiting SIRT4 transcription [69]. Thus, combining therapeutic strategies targeting SIRT4 with glutamine metabolism inhibitors holds promise for chemotherapy sensitization and synergistic treatment. Recent studies have revealed that glutamine not only serves as a metabolic substrate but also functions as a signaling agent, contributing to cancer progression independently of its metabolic roles. For example, extracellular glutamine can activate the STAT3 signaling pathway to promote tumor proliferation [70]. Meanwhile, intracellular glutamine stimulates the activation of mTORC1 [71] and NOTCH signaling pathways [72]. Additionally, within the tumor microenvironment, glutamine depletion prompts tumor cells to enhance glucose uptake and upregulate glutamine synthetase expression through aspartate, thereby increasing glutamine availability and supporting sustained proliferation of tumor cells [73]. In summary, glutamine metabolism participates in tumor metabolic reprogramming through multiple molecular pathways and regulatory mechanisms. Further investigation into the alterations and functional mechanisms of glutamine metabolism in tumors may provide novel therapeutic strategies for cancer treatment. Glutamine metabolism and regulated cell death The intrinsic connection between cell death and metabolism has garnered increasing attention. At present, the close relationship between ferroptosis and metabolic processes has been extensively documented in the literature [74]. Recent advances further indicate that nearly all modes of cell death are closely linked to metabolic reprogramming [8]. As a key metabolic hub, glutamine and its metabolites participate in multiple stages and regulatory networks of regulated cell death, and play an important functional role in it. This section will discuss how glutamine metabolism contributes to regulating multiple forms of cell death and elucidate the role of glutamine in distinct cell death. Autophagy Autophagy is an essential lysosome-dependent self-degradation process within cells, primarily responsible for clearing long-lived proteins, misfolded proteins, and damaged organelles. Therefore, autophagy contributes to maintaining cellular integrity and homeostasis. As a key regulator of cellular metabolism, autophagy modulates multiple biological processes like glucose, glutamine, and lipid metabolism [75]. However, the role of autophagy in tumorigenesis remains controversial. Studies have shown that under nutrient-deficient conditions such as glutamine deprivation, tumor cells strongly depend on autophagy to counteract survival threats [76]. In normal cells, autophagy typically functions as a protective mechanism that defend apoptosis, whereas in cancer cells, excessive autophagy activation may trigger cell death or initiate apoptotic cascades, ultimately determining cell fate [77]. Although several pathways in glutamine metabolism have been shown to directly or indirectly regulate autophagy, whether glutamine activates or inhibits autophagy remains an ongoing debate [78]. During the initiation stage of autophagy, cellular stress—such as nutrient deprivation—activates AMPK, which subsequently inhibits mTORC1 and activates the ULK1 (Unc51-like kinase 1) complex, thereby inducing autophagy [79]. Based on this, researchers revealed that glutamine deprivation suppresses mTORC1 expression via PRKAA2 and induces autophagy in tumor cells [80]. Besides, ATF4 increases Sestrin2 expression, which in turn inhibits mTORC1 activity by blocking its lysosomal localization under glutamine starvation [81]. Meanwhile, autophagy generates glutamine through degradation processes to support cellular metabolism, highlighting a reciprocal regulatory relationship between autophagy and glutamine metabolism [80]. Moreover, under glutamine-restricted conditions, the PI3K-AKT1-FOXO pathway upregulates GS expression, inhibiting mTORC1 and enhancing autophagosome formation, thereby suppressing tumor progression (Fig. 2) [82, 83]. Glutamine metabolism and autophagy. Glutamine and its metabolic byproducts, α-KG and ammonia, serve as key regulators of autophagy initiation. Additionally, glutamine transporters such as SLC1A5 and SLC7A5/SLC3A2 complex contribute to autophagy modulation. Moreover, glutamine-derived GSH further influences autophagy by suppressing the activation of specific transcription factors Glutaminolysis is a vital process in autophagy regulation. It is initiated by GLS catalyzing glutamine to glutamate and further converting it to α-KG. Estrogen has been shown to upregulate GLS expression via c-Myc activation, which in turn suppresses the expression of Beclin-1 and LC3B, thereby inhibiting autophagy and promoting malignant progression. Treatment with CB-839—a potent selective oral bioavailable inhibitor of GLS—significantly reduces tumor cell viability [84]. Interestingly, α-KG can also activate mTORC1 leading to autophagy suppression, whereas metformin restores autophagy flux by activating AMPK, and rescues cancer cells from cell death phenotypes [85]. Furthermore, glutamine deprivation or pharmacological inhibition of key metabolic regulators (e.g., GLS1, mTORC1) significantly enhances the radiosensitivity of prostate cancer (PCa) cells, suggesting that dual targeting of glutaminolysis (via GLS inhibition) and autophagic flux may constitute a synergistic strategy for radiosensitization in PCa [51]. In colorectal cancer cells, suppression of glutaminolysis upregulates ATF4 expression in an m6A-dependent manner and increases DDIT4 level, thereby inhibiting mTOR expression, inducing autophagy and improving patient survival outcomes [86]. In addition, SIRT4 can activate p53 phosphorylation by inhibiting glutamine metabolism, thereby triggering autophagy in PDAC cells [87]. These findings not only underscore the central role of glutaminolysis in autophagy but also offer novel insights for cancer therapies. In addition to α-KG, ammonia—another byproduct of glutaminolysis—also significantly influences autophagy and warrants close attention. Ammonia can induce autophagy through multiple pathways: one pathway is dependent on ULK1 kinase but independent of mTORC1, and another that relies on ATG5. The effect of ammonia on autophagy is dose-dependent, and its activation mechanism exhibits high tissue specificity [88]. Besides, SIRT5 suppresses ammonia production by binding to GLS, thereby further inhibiting ammonia-mediated autophagy [89]. Conversely, BAG3 (Bcl-2 associated athanogene 3) stabilizes GLS expression and promotes glutaminolysis by inhibiting the interaction between GLS and SIRT5, ultimately enhancing autophagy [90]. Like glutamine metabolites, glutamine transporters also play a critical role in the regulation of autophagy. For example, in a mouse model of pancreatic cancer, NEDD4L suppresses autophagy and mitochondrial metabolism by reducing the levels of the ULK1 complex and the SLC1A5, thereby inhibiting pancreatic cancer cell growth and survival [91]. Additionally, glutamine promotes cellular leucine absorption via the SLC7A5/SLC3A2 complex, which in turn activates the mTOR pathway and inhibits autophagy [1]. These findings reveal that glutamine transport serves as both a metabolic cornerstone and a pivotal regulatory nexus in autophagy. Glutamine metabolism is closely linked to oxidative stress, and autophagy acts as a key cellular mechanism against oxidative damage and assists cells in surviving. In this process, GSH, derived from glutamine metabolism, plays a critical role in autophagy induction. Studies have reported that ROS accumulation resulting from GSH depletion can activate transcription factors such as HIF-1α, p53, FOXO3, and Nrf2. These factors then promote autophagy by regulating the transcription of autophagy-related genes, including p62, ATG4, mTOR, Beclin1, and LC3 [92]. The influence of environmental factors such as polystyrene microplastics (PS-MPs) on glutamine metabolism and autophagy also cannot be ignored. PS-MPs have been shown to upregulate hepatic synthesis of glutamine and glutamate, downregulate proteins including PI3K, p-AKT/AKT, p-mTOR, and p62, and enhance the expression of Beclin 1, ATG5, ATG12, and AMPK. These changes elevate the LC3II/LC3I ratio and promote autophagy. Furthermore, PS-MPs suppress levels of HO-1 and NQO1 while increasing the expression of Caspase-8, Caspase-3, and Caspase-9. Through the liver-brain axis, these effects ultimately induce autophagy-dependent ferroptosis and apoptosis in the cerebellum, leading to brain injury [93]. Thus, environmental factors exert profound impacts on cellular metabolism and autophagy. Apoptosis Apoptosis is a form of programmed cell death that eliminates senescent cells in vivo. Through inhibiting apoptotic signaling or activating anti-apoptotic pathway, tumor cells can evade programmed cell death, resulting in tumor survival, therapeutic resistance, and cancer recurrence [94]. Therefore, inducing apoptosis has become key therapeutic strategy in most anticancer treatments. Apoptosis is primarily mediated by two major pathways: the extrinsic and intrinsic pathway. The extrinsic apoptotic pathway is initiated upon ligand binding to death receptors—including Fas, TNFR, and DR3. This binding induces receptor trimerization and recruits adaptor proteins such as FADD, resulting in the assembly of the death-inducing signaling complex (DISC). Subsequently, caspase-8 is activated and propagates the signal by cleaving downstream effector caspases, such as caspase-3, ultimately leading to apoptosis [95]. The intrinsic pathway is activated in response to intracellular stress signals such as DNA damage or oxidative stress. These stimuli increase mitochondrial membrane permeability, resulting in the release of cytochrome c. Then cytochrome c binds to Apaf-1 to form the apoptotic bodies, which activates caspase-9 and downstream effector caspases subsequently [95]. The third mechanism is perforin/granzyme pathway that is mediated by cytotoxic T cells or natural killer cells. Perforin creates pores in the target cell membrane, allowing granzyme B enter to cell and inducing apoptosis. Granzyme B can directly activate caspases, whereas granzyme A induces apoptosis through DNA fragmentation, functioning even in the absence of caspases [96]. Additionally, the Bcl-2 family serves as a critical regulator of apoptosis by modulating mitochondrial permeability. Pro-apoptotic factors such as Bax and Bak promote apoptosis by enhancing membrane permeabilization, while anti-apoptotic proteins like Bcl-2 and Bcl-xL inhibit the activity of pro-apoptotic factors (Fig. 3) [97, 98]. Glutamine metabolism and apoptosis. Glutamine starvation promotes extrinsic apoptosis through modulation of death receptor signaling. GLS enhances apoptosis by regulating mTOR activity, ROS generation, and the expression of Bcl-2 and Bax. Additionally, glutaminolysis induces SQSTM1/p62 accumulation via α-KG production and mTORC1 activation, leading to BAX-dependent caspase-8 cleavage and subsequent glutamoptosis (indicated by blue lines) Glutamine metabolism is closely associated with apoptosis. Various research has demonstrated that glutamine deprivation can induce apoptosis through both extrinsic and intrinsic pathways. Glutamine starvation enhances cellular sensitivity to Fas ligand-, TNF-α-, and HSP70-mediated apoptosis, while also stimulating caspase-2 and caspase-3 activation and cleavage, and it promotes PARP expression and releasing cytochrome c [99]. Notably, GLS1 plays an essential role in triggering apoptosis under glutamine-deficient condition. Studies have shown that exogenous glutamine deficiency promotes the conversion of dimeric GLS1 into self-assembled filamentous polymers that have catalytic activity, thereby depleting intracellular glutamine, leading to insufficient synthesis of aspartate and mitogenome-encoded proteins, and then inducing apoptosis through ROS accumulation [100]. Moreover, this process can be rescued by asparagine supplementation. Furthermore, multiple studies have elucidated the molecular mechanisms behind glutamine metabolism influences apoptosis. For instance, in triple-negative breast cancer (TNBC), ginsenoside CK downregulates GLS1 expression, inhibits glutamine consumption and glutamate production, reduces intracellular ATP levels, and induces GSH depletion along with ROS accumulation, thereby triggering apoptosis [101]. In chronic myeloid leukemia (CML), exosomal hucMSC promotes apoptosis via the miR-146a-5p/USP6/GLS1 pathway [102]. In lung cancer, baicalin interacts with and inhibits the activity of SLC7A5, SLC1A5 and GLS, thereby suppressing mTOR, increasing Bcl-2 expression and decreasing Bax expression and inducing apoptosis consequently [103]. It is noteworthy that several GLS-specific inhibitors have been confirmed to induce cell death, and GLS activity is regulated by oncogenes such as c-Myc and p53 [58]. These findings closely link glutamine metabolism to the progression of malignant tumors and highlight the therapeutic potential of targeting glutamine metabolism to induce apoptosis in cancer treatment. In addition, research on the regulatory mechanisms of glutamine metabolism in the extrinsic apoptosis pathway continues to advance. In PDAC, glutamine influences the expression of cFLIP through a KDM4C-mediated epigenetic mechanism. In detail, inhibition of glutaminolysis increases H3K9me3 levels at the cFLIP promoter, significantly reducing cFLIP expression, which promotes TRAIL-induced DISC formation, thereby enhancing the sensitivity of PDAC cells to TRAIL [104]. Additionally, a study has indicated that suppression of glutamine metabolism upregulates TRAIL-R2 via a GCN2-dependent mechanism and downregulates FLIPL by metabolic stress, resulting in activation of caspase-8 and induction of apoptosis [105]. The survival and growth of many tissues from many primary AML samples and cell lines are dependent on SIRT5, which is a lysine deacylase involved in the regulation of multiple metabolic pathways. Interfering with the expression of SIRT5 can significantly reduce oxidative phosphorylation and glutamine utilization, and induce apoptosis [106]. Recently, studies have unexpectedly revealed that under nutrient-restricted conditions, imbalanced activation of glutaminolysis can induce a special form of apoptosis termed “glutamoptosis” [107]. During glutaminolysis with in the absence of other amino acids, sustained α-KG production and leucine-mediated mTORC1 activation induce SQSTM1/p62 accumulation, which in turn promotes caspase-8 cleavage in a BAX-dependent manner, ultimately leading to glutamoptosis [107]. This unique form of apoptosis offers broad applications prospects for natural compounds and brings opportunities for the development of nutritional science and translational biomedical research [108]. Glutamine metabolism exerts different effects on the treatment with anticancer drugs. Glutamine deprivation attenuates etoposide-induced apoptosis by downregulating p53 expression, which subsequently impairs caspase-8 activation and suppresses apoptotic signaling pathways. Conversely, glutamine depletion enhances cisplatin-induced apoptosis via a reactive oxygen species (ROS)-mediated downregulation of FLIP-S, which subsequently activates caspase-8, promotes Bid cleavage, increases mitochondrial outer membrane permeability, and triggers cytochrome c release [109]. Therefore, inhibiting glutamine metabolism offers novel insights into enhancing tumor cell sensitivity to targeted chemotherapeutic agents. Ferroptosis Ferroptosis is an iron-dependent form of regulated cell death triggered by the accumulation of lipid peroxides, which is mechanistically distinct from apoptosis, necrosis, and autophagy [110, 111]. Intracellular redox imbalance and lipid peroxidation are the core drivers in ferroptosis [112–114]. Lipid peroxidation is a chemical reaction process wherein polyunsaturated fatty acids interact with free radicals. This reaction leads to detrimental effects on lipid-containing biological structures, including cell membranes and lipoproteins [113, 115]. Since ROS are generated in virtually every cellular metabolic process, ferroptosis is closely linked to cellular metabolism. A lot of evidence indicates that both lipid metabolism and amino acid metabolism, particularly cysteine and glutamate metabolism, play critical roles in regulating ferroptosis (Fig. 4) [116]. Glutamine metabolism and ferroptosis. Glutamine supports SLC7A11-mediated GSH production, conferring resistance to ferroptosis. SLC1A5 and SLC38A1 control glutamine influx, modulating cellular sensitivity to ferroptosis. Similarly, GLS2-meidate glutaminolysis elevates ROS levels, promoting ferroptosis. In epigenetics regulation, DOX reduces glutamine availability, upregulating HMOX1 transcription by H3K4me3 modification and enhancing ferroptosis The ferroptosis defense system contains the GPX4-GSH system, the FSP1-CoQH2 system, the DHODH-CoQH2 system, and the GCH1-BH4 system. Among them, the GPX4-GSH system has the closest relationship with glutamine metabolism. GPX4 relies on GSH to scavenge lipid peroxides, while the synthesis of GSH requires glycine, glutamate (generated by glutamine), and cysteine (taken up via SLC7A11 transport) [117]. SLC7A11, a main negative regulator of ferroptosis, exports glutamate to import cysteine, thereby maintaining GSH synthesis. Thus, SLC7A11 acts as a vital hub connecting glutamine metabolism and ferroptosis. In cancer cells with high SLC7A11 expression, the efflux of glutamate leads to a decrease in intracellular glutamate, prompting cells to enhance glutamine uptake and accelerate glutamine catabolism to replenish glutamate. Consequently, cancer cells with high SLC7A11 expression develop a dependence on glutamine [118]. This mechanism renders tumor cells with high SLC7A11 expression sensitive to glutaminase inhibitors, providing potential therapeutic targets for clinical treatment [25, 119]. However, under cystine deficiency condition, glutamine metabolism exhibits a pro-ferroptosis effect. During this process, glutamine accelerates the TCA cycle through glutaminolysis, excessive activates the electron transport chain (ETC), and facilitates the accumulation of ROS, thereby driving ferroptosis [120]. In addition, chronic lymphocytic leukemia cells show extremely low SLC7A11 expression, resulting in a reduced ability to take up exogenous cysteine. In NPM1-mutated AML, the expression levels of cysteine metabolism-related genes are higher, and the cells are more dependent on cysteine. Inhibition of xCT will lead to the depletion of the GSH pool in leukemia cells and trigger partial ferroptosis [121]. Notably, the combination of the hypomethylating agent (HMA) decitabine (DAC) and FINs can enhance the expression of MAGEA6, thereby inhibiting the AMPK-SLC7A11-GPX4 signaling pathway. Ultimately, this combination synergistically promotes ferroptosis, offering a potential therapeutic option for patients with relapsed and refractory AML [122]. Therefore, glutamine metabolism exerts a dual regulatory effect on ferroptosis: under normal circumstances, glutamine metabolism supports GSH synthesis and prevents ferroptosis; whereas, in the absence of cystine, glutamine promotes ferroptosis through the TCA cycle. Similarly, SLC1A5 and SLC38A1 transporters also can influence ferroptosis sensitivity by regulating glutamine uptake [74]. For example, in melanoma, miR-137 targets SLC1A5 and suppresses its expression, thereby reducing glutamine uptake and malondialdehyde accumulation, and conferring resistance to ferroptosis [123]. Besides, research has reported that radiation therapy (RT) can upregulate glutamine and SLC1A5 levels in head and neck squamous cell carcinoma (HNSCC) cells. This alteration increases the expression of IRF1 by activating the interferon signaling pathway. IRF1 further drives the expression of the transferrin receptor, elevates intracellular Fe2⁺ concentration, and induces ferroptosis by disrupting iron homeostasis. Moreover, simultaneously blocking glutamine and CD47 can enhance the therapeutic efficacy of RT and improve the tumor microenvironment [124]. Additionally, increased glutamine uptake mediated by SLC1A5 can lead to elevated lipid peroxidation via the GSH/GPX4 axis and induce ferroptosis [125, 126]. Regarding SLC38A5, elevated SLC38A5 levels in osteosarcoma can mediate the activation of the PI3K/AKT/mTOR signaling pathway through glutamine transport, subsequently enhancing the SREBP1/SCD-1 signaling pathway, inhibiting ferroptosis in osteosarcoma cells, and ultimately promoting the growth and metastasis of tumor cells [127]. Apart from glutamine transporters, the mitochondrial glutamate carriers SLC25A18 and SLC25A22 are also implicated in ferroptosis. In PDAC cells, the loss of SLC25A22 reduces GSH levels and enhances the susceptibility of tumor cells to ferroptosis [128]. Glutaminolysis is a highly active metabolism pathway in tumor tissues that is important for their growth. This process fuels the TCA cycle and supports the occurrence of ferroptosis. Both glutaminolysis and its downstream TCA cycle can induce mitochondrial membrane potential (MMP) hyperpolarization, promote lipid peroxidation, and subsequently activate ferroptosis [129]. Mechanistically, GLS2 promotes ferroptosis by enhancing the conversion of glutamate to α-KG, increasing lipid ROS levels [130]. Moreover, the accumulated glutamine-derived metabolite α-KG can be further converted by malate dehydrogenase 1 (MDH1) into 2-hydroxyglutarate (2-HG), which exacerbates ROS production and induces ferroptosis through promoting lipid peroxidation and DNA damage by TP53 activation [131]. Notably, supplementation with α-KG or its downstream metabolites—including succinate, fumarate, and malate—can rescue cells from death caused by combined glutamine and cysteine deprivation [132]. Conversely, inhibiting glutaminolysis reduces ROS levels, suppresses ferroptosis, and alleviates cardiac injury induced by ischemia/reperfusion [132]. However, glutamine exhibits a protective role against ferroptosis under pathological conditions such as intervertebral disc degeneration (IDD). In brief, glutamine stabilizes nuclear factor erythroid 2-related factor 2 (Nrf2) by inhibiting its ubiquitin–proteasome degradation, thereby suppressing lipid peroxidation, and protecting nucleus pulposus (NP) cells from tert-butyl hydroperoxide (TBHP)-induced ferroptosis [133]. Moreover, glutamine can enhance the sensitivity of cells to ferroptosis through epigenetic reprogramming. For instance, glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) upregulates H3K4me3 levels and HMOX1 transcription via PAXIP1, activating the ferroptosis pathway and increasing the sensitivity of PDAC cells to GPX4-dependent ferroptosis [134]. Together, these findings elucidate the bidirectional regulatory role of glutamine metabolism in controlling ferroptosis via modulation of GSH and ROS homeostasis. Cuproptosis Copper is one of the essential microelements in the human body. As cofactors for various enzymes, they are extensively involved in key physiological processes such as mitochondrial respiration, iron metabolism, and antioxidant defense [135]. Although copper ion-induced cell death was first observed in the 1980s, its molecular mechanism remained elusive until 2022, when it was formally characterized as a novel form of regulated cell death termed cuproptosis. Cuproptosis relies on the direct binding of copper ions to lipoylated proteins in the TCA cycle, triggering the oligomerization and abnormal aggregation of lipoylated proteins, while also leading to the degradation of iron-sulfur cluster proteins (Fe-S). Thus, a protein toxicity stress response is induced, resulting in cell death [136]. The protein lipoylation process is regulated by ferredoxin 1 (FDX1) and lipoyl synthase (LIAS) [137]. Moreover, FDX1 not only mediates protein lipoylation but also reduces Cu2⁺ to the more toxic Cu⁺ and exacerbates cell death by reducing the levels of Fe-S cluster proteins (Fig. 5) [138]. Glutamine metabolism and cuproptosis. Glutamine metabolism enhances GSH synthesis, chelating cytoplasmic copper iron to prevent cuproptosis. Besides, excessive Cu2⁺ uptake activates glutamine transporters (e.g., SLC38A1, SLC1A5, SLC1A4, SLC38A2), elevating intracellular glutamine levels and creating a positive feedback loop It is noteworthy that glutamine metabolism and cuproptosis exhibit a mutually regulatory relationship. On one hand, glutamine-derived GSH can protect tumor cells from copper ion-induced cell death by chelating copper ions [139]. On the other hand, excessive copper ion uptake is accompanied by the activation of glutamine transporters SLC38A1, SLC1A5, SLC1A4, and SLC38A2, further increasing intracellular glutamine levels [140]. Besides, in immune cells, SARS-CoV-2 infection can reduce glutamine levels, leading to increased cuproptosis in immune cells through decreased GSH levels and copper overload, which may further promote tumor progression [141]. Based on these mechanisms, therapeutic strategies targeting cuproptosis have become a research hotspot. Recently developed BPTES-loaded biomimetic Cu-doped polypyrrole nanoparticles (CuP) demonstrate dual-modal efficacy by suppressing GLS1 activity to inhibit GSH synthesis and compromise cellular antioxidant capacity, while concurrently releasing Cu2⁺ to induce DLAT oligomerization. These two mechanisms synergistically induce cuproptosis in breast cancer [142]. Therefore, the development of copper-based nanomaterials provides a new idea for tumor treatment. Disulfidptosis Disulfidptosis is a recently identified form of cell death that occurs under glucose deprivation conditions. In this process, cells exhibiting elevated SLC7A11 expression undergo aberrant cysteine uptake, resulting in pathological accumulation of intracellular disulfide bonds and subsequent destabilization of the cytoskeletal architecture, ultimately triggering disulfidptosis [143]. Emerging evidence indicates that inhibiting glutamine and glucose metabolism can induce disulfidptosis in tumor cells, demonstrating significant therapeutic potential in suppressing primary tumor progression. Building on these findings, Yang Li et al. engineered a transformable human serum albumin nanocapsule (HGV)-based co-delivery system, which loads both SLC1A5 inhibitor V9302 and glucose oxidase (GOX). This nanocapsule synergistically depletes NADPH pools, blocks intracellular disulfide decomposition, disrupts redox homeostasis, ultimately facilitating disulfidptosis [144] Nevertheless, the precise molecular interplay between disulfidptosis and glutamine metabolic pathways remains incompletely understood and warrants further mechanistic investigation (Fig. 6A). Glutamine metabolism and disulfidptosis and necroptosis. A. SLC1A5 inhibition-mediated glutamine depletion promotes ROS accumulation to induce disulfidptosis. In addition, cells with high SLC7A11 expression induce aberrant cysteine uptake, leading to intracellular disulfide overload and subsequent disulfidptosis. B. Inhibition of GLS1 and elevation of ROS levels enhance RIPK3 phosphorylation, releasing DAMPs and inducing necroptosis. Moreover, activated RIPK3 can directly interacts with GLUD1 to promote α-KG production Necroptosis Necrosis is an unregulated form of cell death triggered by external physical and chemical stress, whereas necroptosis is a highly regulated programmed cell death process. Necroptosis acts as a gatekeeper in host defense against pathogen invasion, and its dysregulation is closely associated with degenerative diseases, inflammatory disorders, and cancer [145, 146]. Necroptosis can be triggered via a range of innate immune signaling pathways, such as TNFα, LPS, and TRAIL. Upon activation, these signaling molecules induce the phosphorylation and activation of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and RIPK3, which in turn activate the executioner protein mixed-lineage kinase domain-like (MLKL). Then, this leads to rapid permeabilization of the plasma membrane, release of cellular contents—damage-associated molecular patterns (DAMPs)—and causes caspase-independent cell death (Fig. 6B) [147, 148]. The relationship between glutamine metabolism and necroptosis remains understudied. Current studies report that a photo-responsive biomimetic nanosystem, R-CM@MSN@BC, exhibits responsiveness to ROS and controls the release of glutamine metabolism inhibitor bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl) ethyl sulfide (BPTES), thereby inhibiting GLS1. Meanwhile, this intervention promotes RIPK3 phosphorylation, which promotes the release of DAMPs and enhances the efficacy of cholangiocarcinoma immunotherapy by inducing necroptosis [149]. Besides, glutaminolysis has been shown to promote RIPK3-mediated ROS generation, which contributes to TNF-induced necroptosis [150]. But the precise mechanisms behind this require further investigation. Additionally, activated RIPK3 can directly interact with glutamate dehydrogenase 1 (GLUD1), a key enzyme in glutaminolysis, thereby augmenting the catalytic activity of GLUD1. Consequently, the production of α-ketoglutarate (α-KG) is elevated in macrophages, which fosters M2 macrophage activation while suppressing M1 polarization, thereby contributing to the establishment of endotoxin tolerance (ET) [151]. Beyond glutamine, its metabolite glutamate is also implicated in necroptosis. Impaired synaptic clearance of glutamate can lead to glutamate excitotoxicity, which promotes necroptosis in retinal ganglion cells (RGCs) through activating the RIPK1/RIPK3/MLKL pathway. Furthermore, both RIPK3 and RIPK1 inhibitors have been shown to mitigate glutamate-induced RGC loss, retinal damage, neuroinflammation, excessive ROS production, and reduced GSH levels [152]. Although several studies have reported associations between glutamine metabolism and necroptosis, the molecular mechanisms through which glutamine metabolism regulates necroptosis in cancer remain to be fully elucidated. In general, glutamine acts as a protector in normal cells, maintaining physiological balance. But in tumor cells, its metabolism is reprogrammed, utilizing α-KG, mTORC, and GSH to trigger diverse cell deaths. From the perspective of nutrient supply, glutamine deficiency disrupts normal metabolic processes, triggering autophagy, apoptosis, glutamoptosis, and necroptosis. In terms of oxidative stress, GSH depletion is a key driving factor. When ROS accumulate significantly, various cell death modes including ferroptosis, cuproptosis, autophagy, apoptosis, and disulfidptosis may be activated. Additionally, the oncogenic background of tumor cells cannot be ignored. Oncogenes can regulate the expression or activity of key enzymes in glutamine metabolism, such as GLS, thereby mediating cell death like apoptosis. Glutamine metabolism also influences the crosstalk between different cell death modes. Studies show that treating SLC1A5-knockdown cells with cisplatin induces ferroptosis, apoptosis, and autophagy, suggesting glutamine deficiency can drive multiple types of cell death [153]. Notably, glutamine metabolism is not only closely related to multiple cell death modes but also participates in the conversion process between them. For instance, excessive autophagy can mediate various other cell death modes [154]. In the context of ferroptosis, ferritin degradation relies on autophagy, and overexpressing NCOA4 promotes this process. Knocking out ATG5 inhibits Erastin-induced ferroptosis and reduces ferrous ions and lipid peroxidation [155]. As mentioned earlier, PS-MPs can induce autophagy-dependent ferroptosis and apoptosis by promoting hepatic glutamine synthesis, upregulating ATG5 expression, and inhibiting HO-1 and NQO1 expression levels. Regarding apoptosis, autophagy plays a dual role, either inducing or suppressing it. In this process, mTOR exerts bidirectional effects on apoptosis through both autophagy-dependent and autophagy-independent mechanisms [156]. Interestingly, autophagy inhibition is a critical step enabling glutamoptosis. Some scholars propose that when cells are subjected to low-level stimuli, autophagy dominates, and when fatal stress occurs, apoptosis is initiated [157]. For example, shikonin can induce intracellular ROS generation, promote cell necroptosis, and activate RIP3 to interfere with autophagy flux. The autophagy marker p62 can activate Nrf2 to counteract ROS, reflecting the protective role of autophagy in response to stress related to necroptosis [158]. Moreover, glutamine, as a GSH raw material, affects autophagy-necroptosis interaction via ROS. Despite many reports on glutamine metabolism’s role in cell death regulation, the specific thresholds for promoting/inhibiting death and its role in death mode conversion remain unclear. Future research should focus on this to uncover the mysteries of glutamine metabolism in the cell death network. The role of glutamine metabolism in tumor microenvironment Cancer cells rely on glutamine as a critical nutrient for survival and proliferation, while immune cells require glutamine for activation and expansion. Notably, the rate of glutamine consumption by these cells can be comparable to that of glucose. Within the TME, competition for glutamine between cancer cells and immune cells has become a major research focus [159]. Some researchers propose that a dynamic glutamine competition model exists between tumor and immune cells [160]. Cancer cells employ multiple mechanisms to gain a competitive advantage over immune cells in acquiring and utilizing glutamine, whereas immune cells depend on sufficient glutamine supply to sustain their functions and antitumor activity [161]. Numerous in vitro and in vivo studies have confirmed that glutamine is essential for the survival, proliferation, and functional maintenance of various immune cells. Also, glutamine metabolism plays a critical role in regulating lymphocyte expansion, cytokine production, phagocytic activity, and secretory function of phagocytes, as well as the cytotoxic activity of neutrophils, among other immune processes [162]. Therefore, a deeper understanding of the role of glutamine metabolism in the TME is of great significance for enhancing the efficacy of tumor immunotherapy. The impact of glutamine metabolism in immune cells T lymphocytes T cells play a crucial role in maintaining health and preventing disease. Upon antigen stimulation, naïve T cells differentiate into CD4⁺ helper T cells, CD8⁺ cytotoxic T cells, and memory T cells, which mediate immunoregulatory functions, direct cytotoxicity, and confer long-term protective immunity, respectively [163]. The activation status of T cells significantly influences their glutamine metabolism: quiescent T cells exhibit reduced glutamine utilization, whereas activated effector T cells enhance glutamine metabolism to meet the demands of rapid cell division and the synthesis of proteins and nucleic acids [164, 165]. In acute kidney injury, reducing glutamine availability or treating mice with glutamine antagonists (JHU083) markedly suppresses activation and proliferation of T cells [166]. This metabolic characteristic underscores the importance of glutamine in regulating T cells function. Nevertheless, in the complex and dynamic "battlefield" of the tumor microenvironment (TME), there is fierce competition for glutamine between tumor cells and T cells. Given their divergent metabolic profiles, targeting glutamine metabolism exerts different effects on these two cell types, ultimately contributing to the establishment of an anti-tumor microenvironment [167]. Present research has further revealed that glutamine metabolism modulates T cell function and differentiation through diverse and complex regulatory mechanisms. First, mTOR acts as a sensor of glutamine availability and regulates T cell activity in the TME. Glutamine deprivation inhibits mTOR activity, which affects T cell proliferation via the c-Myc signaling pathway and promotes differentiation into Treg cells [168–170]. Moreover, SLC1A5 has been identified as essential for coupling TCR and CD28 to activate the mTORC1 pathway [171]. In liver cancer, the mevalonate pathway enzyme PMVK reprograms glutamine metabolism, significantly promoting the synthesis and release of 4-acetylaminobutyric acid (4-Ac-GABA) into the TME. 4-Ac-GABA then suppresses CD8⁺ T cell activation, infiltration, and antitumor responses by activating GABAA receptors on CD8⁺ T cells [172, 173]. Additionally, integrated metabolomic and transcriptomic analyses have identified the glutamine transporter SLC25A22 as a key molecule that enhances the cytotoxicity of CD8⁺ T cells and improves the efficacy of PD-1 blockade therapy [174]. Reprogramming glutamine metabolism in multiple myeloma may enhance the anti-tumor function of CAR T cells [175, 176]. Also, glutamine modulates T cell gene expression through epigenetic regulations. A high-salt diet increases glutamine consumption and induces epigenetic remodeling, thereby enhancing the effector function of CD8⁺ T cells and suppressing tumor growth [177]. Among T cell subsets, aberrant activation of GLS1-mediated glutaminolysis promotes Th17 cells differentiation by enhancing H3K9Ac and H3K27Ac in the IL17A gene promoter [178]. In addition, PPARγ agonists suppress Th17 cells responses by inhibiting the GLS1-dependent glutaminolysis/2-HG/H3K4me3 and GSH/ROS axis pathways [179]. Moreover, IL-6 downregulates GLS expression in CD4⁺ T cells, thereby inhibiting glutaminolysis, enhancing Th1 polarization and IFN-γ production, consequently improving antitumor immunity [180]. In cancer therapy, inhibiting glutamine metabolism not only reduces tumor cells consumption of glutamine but also meets the glutamine demand of lymphocytes within the tumor tissues, thereby enhancing the efficacy of PD-L1 blockade therapy [181]. Furthermore, blocking glutamine facilitates the infiltration of CD8⁺ T cells and Th1 T cells, thereby enhancing the efficacy of EGFR peptide vaccines in inhibiting the EGFR-driven development and growth of lung cancer [182]. In CAR-T cell therapy, in vitro glutamine inhibition, using antagonists such as DON (6-diazo-5-oxo-L-norleucine) or CB-839 (a GLS inhibitor), effectively modulates T cells metabolism and differentiation, which effectively enhances therapeutic outcomes [39, 183, 184]. These studies reveal the multiple regulatory roles of glutamine metabolism in function and differentiation of T cells, highlighting its potential applications in disease treatment (Fig. 7A). Regulation roles of glutamine in the TME. Tumor cells engage in intense competition with cells within the TME for glutamine, as illustrated in the left panel. The right panel elucidates the diverse impacts of glutamine on distinct immune cells. A. Glutamine competition between tumor cells and T cells or JHU083-mediated inhibition of glutamine metabolism in T cells suppresses T-cell proliferation and activation, reduces the Teff activity and the Th17 differentiation, and increases Treg abundance. In addition, tumor cell-induced glutamine deprivation in cDCs impairs their antigen presentation capacity, thereby attenuating T cell-mediated tumor killing. B. Enhanced glutamine uptake promotes cytokine and antibody production in B cells and facilitates the differentiation of plasma cells and memory B cells. C. IL-2 upregulates SLC1A5 expression in NK cells, increasing glutamine uptake and enhancing IFN-γ production. Conversely, glutamine deficiency reduces c-MYC levels and compromises NK cell function. Furthermore, myCAF-derived exosomal PWAR6 upregulates SLC38A2 in tumor cells by inhibiting Nrf2 degradation, promoting glutamine utilization in tumor cells and suppressing NK cell-mediated cytotoxicity. D. Glutamine supplementation drives macrophage polarization toward the anti-tumor M1 phenotype, whereas glutamine deprivation favors M2 polarization. E. The glutamine inhibitor JHU083 suppresses tumor growth by downregulating CSF3 expression and simultaneously induces apoptosis and M1-like polarization of MDSCs, facilitating T cells recruitment and tumor cells elimination B lymphocytes The metabolic characteristics of B cells are similar to those of T cells, and glutamine also serves as a fundamental energy source that plays a critical role in B cell function and differentiation. The differentiation of B cells into plasma cells and memory B cells depends on glutamine availability, and antibody production as well as cytokine secretion are closely linked to glutaminolysis [185, 186]. In contrast, glutamine deficiency significantly impairs the differentiation of memory B cells and plasma cells [187, 188]. These findings have prompted further investigation into the mechanisms by which glutamine metabolism regulates B cell function and differentiation. Inhibition of SLC1A5 markedly reduces IgM production, which reveals that glutamine transporters play a key role in regulating immunoglobulin synthesis within B cells [185]. Moreover, the mTOR signaling pathway is instrumental in glutamine-mediated regulation of B cell differentiation. For instance, the activation of mTOR inhibits glycogen synthase kinase-3 (GSK3) signaling and fosters the production of IL-10-expressing regulatory B cells (B10 cells) that rely on glutaminolysis [189]. In addition, intermediate metabolites derived from glutamine metabolism can also influence B cell differentiation. Glutamine-derived α-KG can enhance the expression of key transcription factors such as T-bet and BATF in atypical memory B cells, thereby promoting AtM B cells differentiation. This process endows AtM B cells with the ability to suppress T cell responses and contribute to an immunosuppressive microenvironment [40]. Moreover, targeting glutamine metabolism in disease models has also demonstrated significant effects. In MRL/lpr mice, inhibition of glutaminolysis using the GLS1 inhibitor CB-839 not only markedly reduced B cell numbers but also decreased the population of TfH cells, thereby ameliorating disease phenotypes through modulation of glutamine metabolism [190]. Hence, these results not only underscore the essential role of glutamine metabolism in regulating B cell function, but also provide new insights and potential clinical targets for immune-related diseases (Fig. 7B). Natural killer cell (NK cells) As a critical subset of effector cells in the innate immune system, NK cells are capable of not only directly lysing malignant tumor cells, but also mediating antibody-dependent cell-mediated cytotoxicity (ADCC) and modulating the functional activities of T lymphocytes [191, 192]. In NK cells, IL-2 upregulates SLC1A5 expression, thereby enhancing glutamine uptake and promoting IFN-γ production [193]. Conversely, glutamine deficiency leads to reduced c-MYC levels, resulting in impaired cell proliferation and compromised NK cells’ function [194, 195]. In CRC, myofibroblast-derived exosomal PWAR6 inhibits Nrf2 degradation by competitively binding to Keap1, which upregulates SLC38A2 expression and promotes glutamine uptake by CRC cells, while it reduces glutamine availability for NK cells and facilitates immune evasion [196]. Unlike CD4⁺ T cells, NK cells exhibit higher basal glutamine levels and show significantly increased glutaminolysis upon activation. This metabolic adaptation supports TCA cycle and GSH production, indicating that targeting NK cell-specific glutamine metabolism could be advantageous for treating diseases with nutrient restrictions (Fig. 7C) [197]. Dendritic cells (DCs) As antigen-presenting cells within the immune system, DCs function as commanders in the human immune system. Current research on DCs and glutamine metabolism remains at the exploratory stage. Clinical cohort analyses have identified GLS and GOT2 as biological markers closely associated with DC cells, demonstrating better responsiveness to immunotherapy in breast cancer patients [198]. Besides, nuclear receptor co-repressor 1 (NCoR1) deletion in DCs leads to reduced pyruvate oxidation and glutaminolysis, which promotes an immune-tolerant phenotype in these cells [199]. Conventional dendritic cells (cDCs), which possess typical antigen-presenting functions, are divided into two distinct subsets: cDC1s and cDC2s. Among these, cDC1s demonstrate higher glutamine dependency, and glutamine may partially influence their differentiation, proliferation, and survival through the mTORC1 pathway [200]. A recent study has reported that tumor cells can suppress cDC1-mediated CD8⁺ T cell activation by regulating glutamine allocation in TME, thereby constructing an immunosuppressive niche for immune evasion [161]. This observation highlights the importance of glutamine as a keystone in the metabolic dialogue that governs tumor-immune cell interactions. Macrophages Macrophages regulate the adaptive immune system by engaging in phagocytosis and secreting a variety of cytokines, chemokines and growth factors, thereby exerting pro-tumor or anti-tumor effects [201, 202]. Tumor-associated macrophages (TAMs) modulate their activation status, synthesis of inflammatory cytokines (such as IL-1, IL-6, and TNF-α), antigen presentation, phagocytic function, and peroxisome proliferation by regulating glutamine metabolism. In terms of macrophage polarization, studies have shown that a high α-KG/succinate ratio promotes polarization toward the M2 phenotype, whereas a low α-KG/succinate ratio activates pro-inflammatory M1 macrophages [41]. Additionally, glutamine supplementation tunes the NAD⁺/NADH ratio through the glutamine-lactate shuttle, thereby enhancing fatty acid oxidation and promoting pro-inflammatory functions and anti-tumorigenic polarization in macrophages [38]. Furthermore, cigarette smoke extract (CSE) establishes a microenvironment conducive to oral mucosal precancerous lesions by modulating glutamine metabolism and promoting M2 macrophage polarization [203]. Recent studies have elucidated that aspartate generated through glutaminolysis serves as an indispensable substrate for EIF5A-dependent non-canonical translation of HIF-1α, a process critically regulating TAM polarization [204]. Consistent with above studies, glutamine deprivation inhibits M2 polarization and the production of the chemokine CCL22, while inhibition of GS promotes a shift from the M2 to M1 phenotype [205, 206]. Interestingly, M2 polarization itself activates glutaminolysis, suggesting a bidirectional regulatory relationship between glutamine metabolism and macrophage polarization [207] (Fig. 7D). Neutrophils Compared to other leukocytes, such as macrophages and lymphocytes, neutrophils exhibit a higher rate of glutamine consumption [208]. A study has shown that elevated glutamate levels can trigger the expression of immunosuppressive genes—including STAT3, ARF4, and RAB10—in neutrophils, thereby promoting an immunosuppressive phenotype [160]. Besides, glutamine mitigates neutrophil apoptosis by suppressing the expression of pro-apoptotic proteins Bax and Bcl-xs [209]. Neutrophil extracellular traps (NETs) are fibrous networks released by neutrophils into the extracellular environment upon stimulation. These networks are composed of neutrophil-derived nuclear, cytoplasmic, and granular proteins. The formation of NETs relies on ROS, myeloperoxidase (MPO), and neutrophil elastase (NE) [210]. While NETs participate in all stages of tumor development, their pro- or anti-tumorigenic effects are determined by immune state and TME interactions [211]. Research has revealed that glutamine can enhance NET formation by supporting ATP production and regulating NADPH oxidase, thereby increasing superoxide generation [212]. Notably, neutrophils also utilize glutamine for intercellular positive feedback communication: glutamate released by neutrophils can induce adjacent cells to reciprocally release glutamate [213]. Myeloid-derived suppressor cells (MDSCs) MDSCs originate from myeloid progenitor cells and immature myeloid cells, with the potential to differentiate into dendritic cells, macrophages, and granulocytes [214–216]. The maintenance of immunosuppressive function in MDSCs is closely associated with glutamine metabolism. Activation of the STAT3 signaling pathway drives glutamine consumption via the TCA cycle, while the glutamine-derived metabolite itaconate significantly prolongs MDSC survival by downregulating mitochondrial ROS levels through Nrf2-mediated pathways [217]. The substantial impact of tumor cell-mediated glutamine competition on immune cells cannot be overlooked. Glutamine competition between cancer cells and immune cells in the TME Notably, the competition for glutamine among different cell types in the TME introduces an additional layer of complexity (Fig. 7). Tumor cells with glutamine addiction can absorb extracellular glutamine that is needed by lymphocytes, thereby impairing antitumor immune responses [167]. For example, in a 3D tumor-immune cell coculture spheroid model, breast cancer cells exhaust glutamine in the TME and subsequently block T cell function [218]. Additionally, glutamine deprivation not only attenuates effector T cell (Teff) activity but also increases the number of regulatory T cells (Tregs) [160]. On the contrary, replenishing glutamine in the TME can restore T cell infiltration and slow tumor growth [219]. However, the metabolic plasticity of cancer cells and effector T cells differs markedly in vivo, leading to divergent responses to glutamine inhibition. In tumor-bearing mouse models, glutamine blockade suppresses both oxidative metabolism and glycolysis in cancer cells, resulting in hypoxia, acidosis, and reduced nutrient consumption. In contrast, effector T cells respond to glutamine antagonism by significantly upregulating oxidative metabolism and adopting a long-lived, highly activated phenotype that sustains functionality [220]. These distinct metabolic and functional reprogramming mechanisms provide a basis for achieving effective antitumor responses. Therefore, maintaining appropriate glutamine levels is critical for shaping the immune microenvironment and may serve as a “metabolic checkpoint” in cancer immunotherapy. It is important to emphasize that the TME exhibits greater complexity than conventionally recognized, and the impact of glutamine metabolism extends beyond these two cell types. A study showed that tumor cells express higher levels of SLC38A2 compared to cDC1s, leading to glutamine starvation in conventional dendritic cells (cDC1s). This disrupts the assembly of the FLCN–FNIP2 complex, enhances TFEB activity, reduces antigen presentation capacity of cDC1s, and consequently, which creates favorable conditions for tumor growth by impairing CD8⁺ T cell formation [161]. Numerous studies reveal that various strategies for inhibiting glutamine metabolism exert different impacts on T cells, probably owing to differences between in vitro and in vivo settings, TME heterogeneity, or differences in the metabolic profiles among distinct cell subsets. This implies that when different strategies are used to target the identical metabolic pathway, it can result in opposing metabolic and functional alterations, thereby highlighting the urgent need for precise intervention in the metabolic pathways and functions of immune subsets in the TME. Cancer-associated fibroblasts (CAFs) are the main stromal elements in the tumor microenvironment (TME). They synthesize and release glutamine, fueling tumor cell survival and proliferation [221, 222]. Notably, CAFs also utilize glutamine to produce proline, driving the formation of a collagen-rich extracellular matrix and promoting tumor development and invasion [223]. Research indicates that CAF-specific LINC01614 is shuttled to LUAD cells via exosomes, activating NF-κB and upregulating SLC38A2/SLC7A5 to enhance glutamine uptake. Meanwhile, IL-6 secreted by LUAD cells upregulates LINC01614 in CAFs, creating a positive feedback loop [50]. Besides, tumor cells activate Syk-NF-κB to polarize inflammatory fibroblasts and induce IL-6-driven glutamine synthesis. Furthermore, they promote the polarization of TAMs and support tumor growth by altering the composition of TAMs [224]. This indicates that CAFs play a crucial role in shaping an immunosuppressive TME. Targeting glutamine uptake can disrupt nutrient exchange between cancer cells and CAFs, suppress activated CAFs, and reduce extracellular matrix secretion. For instance, co-delivering V9302 (an SLC1A5 inhibitor) and siGLUT to CAFs disrupts glutamine metabolism and enhances drug efficacy. Additionally, neutralizing antibodies against NetG1 inhibit glutamine synthesis, reducing CAF-derived metabolites and cytokines to slow PDAC progression [225]. Besides, glutamine metabolism modulates the crosstalk between tumor cells and macrophages. For instance, tumor cells with GFPT2 overexpression demonstrate heightened glutaminolytic flux, which attenuates mitochondrial fission dynamics and disrupts WASP-WIP phase separation in macrophages, thereby contributing to therapy resistance in patients [226]. Moreover, targeting glutamine metabolism can also induce apoptosis of myeloid-derived suppressor cells (MDSCs) and facilitates their conversion into pro-inflammatory macrophages [227]. This remodeling of the TME enhances antitumor immunity, which underscores a tight metabolic interplay between tumor cells and immunosuppressive cells. Glutamate secreted by tumor cells also induces an immunosuppressive phenotype in neutrophils and MDSCs, as well as promotes M1 polarization of macrophages. Small-molecule inhibitors targeting glutamine metabolism exhibit dual effects in vivo: they suppress tumor growth while markedly inhibiting the generation and tumor infiltration of MDSCs. Mechanistic studies revealed that inhibiting tumor glutamine metabolism reduces CSF3 levels, enhances immunogenic cell death of MDSCs, and promotes the infiltration of inflammatory TAMs, thereby remodeling the tumor immune microenvironment. Furthermore, inhibition of glutamine metabolism in MDSCs triggers cell death and drives their conversion into inflammatory macrophages [227]. Therefore, this intricate competition for glutamine between tumor cells and MDSCs offers new perspectives for reversing immunosuppressive states (Fig. 7E). In summary, glutamine-addicted tumor cells compete with immune cells for glutamine in TME, weakening anti-tumor immune cell infiltration and function. Moreover, tumor cells interact with pro-tumor immune cells on CAFs for immune evasion. Given their different responses to glutamine inhibitors, targeting glutamine metabolism can inhibit tumor growth, remodel TME, and provide new insights into reversing immunosuppression. Targeting glutamine metabolism for antitumor therapy The metabolic reprogramming that supports cancer cell survival and proliferation has been recognized as one of the established hallmarks of cancer. This characteristic renders cancer cells vulnerable to metabolism-based therapeutic agents. Since glutamine is a pivotal energy source for many cancers, glutamine deprivation therapy has undoubtedly emerged as a hot topic in cancer treatment in recent years. In cancer diagnosis, 18F-fluorinated glutamine (18F-(2S,4R)4-fluoroglutamine, 18F-FGln) has been developed as a potential tumor imaging tracer, and has demonstrated promising results in both animal model validation and clinical evaluation of 18F-FGln PET for glioma [228, 229]. Currently, numerous studies have revealed encouraging anticancer effects by targeting every step of glutamine metabolism. Intervention strategies include glutamine deprivation, restriction of glutamine uptake, reduction of glutamine metabolic enzyme activity, utilization of glutamine analogs, and disruption of glutamine metabolism regulators. Hence, scholars have categorized glutamine metabolism-targeted drugs into three major classes: (1) Glutamine antimetabolites, (2) Glutamine uptake inhibitors, (3) Glutamine catabolic-related enzymes inhibitors (Table 1) [160]. Table 1Agents targeting glutamine metabolism in cancerDrugsTargetExperimental phaseCancer typesRefs.Glutamine antimetabolitesL-DON + BPTES–Preclinical phaseMelanoma[230]L-DON + ASNaseASNSPreclinical phasePDAC[231]DRP-104–Preclinical phaseLung cancer[233]DRP-104 + trametinib–Preclinical phasePDAC[272]JHU083–Preclinical phaseBladder cancer[234]JHU083 + EGFR peptide vaccine (EVax)–Preclinical phaseLung cancer[182]Glutamine uptake inhibitorsV-9302SLC1A5Preclinical phaseBreast cancer, Colorectal cancer[236]PPa/V-9302 NPsSLC1A5Preclinical phaseBreast cancer, Colorectal cancer[174, 237]V-9302 + anti-PD-1SLC25A22Preclinical phase3D-CSCC organoids[174]GPNASLC1A5Preclinical phaseLung cancer, Breast cancer[238, 239]BenzylserineSLC1A5Preclinical phaseBreast cancer, Endometrial carcinoma[235, 273]JPH203SLC7A5Phase-I clinical trialSolid tumors[252]GilteritinibSLC38A2Preclinical phaseAcute myeloid leukemia[250]ErastinSLC7A11Preclinical phaseMany types of tumor cells[274]SulfasalazineSLC7A11Preclinical phaseMany types of tumor cells[243]SulfasalazineSLC7A11Phase-I clinical trialGastric cancer[244]SorafenibSLC7A11Preclinical phaseMany types of tumor cells[275]SorafenibSLC7A11Phase-III clinical trialHCC, RCC, Thyroid cancer[245, 246]MeAIBSLC38A1/A2Preclinical phaseMelanoma[251]Glutamine catabolic-related enzymes inhibitorsCB-839GLSPreclinical phaseTNBC, Acute myeloid leukemia, Myeloproliferative neoplasms, Gastric cancer, Colorectal cancer, RCC, Ovarian carcinoma[253–256, 258, 259, 276]CB-839 + AzacytidineGLSPhase 1b/2Myelodysplastic syndromes[277]CB-839 + PanitumumabGLSPhase I/IIColorectal Cancer[257]BPTESGLSPreclinical phasePancreatic cancer, Breast Cancer, TNBC[142, 262, 278, 279]BPTES + CisplatinGLSPreclinical phaseOvarian cancer[263]BPTES + 5-FUGLSPreclinical phaseNSCLC[280]C968 + anti-PD-L1GLSPreclinical phaseOvarian Cancer[264]C968 + AdriamycinGLSPreclinical phaseBreast cancer[265]C968 + Ce6GLSPreclinical phaseBreast cancer[266]R162GLUD1 inhibitorPreclinical phaseLung cancer, Breast cancer[268, 269]AOAAminotransderase inhibitorPreclinical phaseBreast Cancer[270]AOA + regorafenibAminotransderase inhibitorPreclinical phaseHCC[271]CPD-3BGLSPreclinical phaseHCC, Colon cancer[281, 282]EGCGGLSPreclinical phaseTNBC[283]HYL001GLSPreclinical phaseBreast cancer, HCC[267] Agents targeting glutamine metabolism in cancer JHU083 + EGFR peptide vaccine (EVax) Glutamine antimetabolites As a critical class of therapeutic agents, glutamine antimetabolites achieve irreversible inhibition of glutamine metabolism by competing with glutamine. These inhibitors broadly suppress glutamine metabolic pathways and primarily include 6-nitro-5-oxo-L-norleucine (L-DON), DRP-104, and JHU083. The combination of L-DON with the glutaminase inhibitor BPTES significantly reduces the survival rate of MAPKi-resistant cells [230]. Additionally, L-DON suppresses aspartate biosynthesis by inhibiting asparagine synthetase (ASNS). When combined with L-asparaginase (ASNase), this synergistic strategy demonstrates marked efficacy in suppressing metastatic progression of PDAC [231]. It is noteworthy that the prodrug form of L-DON, DRP-104 (Sirpiglenastat), also exhibits potent antitumor effects. Studies indicated that DRP-104 suppresses glutamine-dependent nucleotide synthesis, enhances antitumor T cell responses, and effectively inhibits the growth of KEAP1-mutant tumors. Moreover, in Kras-mutant tumors with or without Stk11 mutations, the deletion of Keap1 renders immunocompetent mice sensitive to DRP-104 when administered as a single-agent therapy [232]. Currently, DRP-104 is undergoing clinical evaluation, with its therapeutic potential in combination with immune checkpoint treatments, which shows significant promise for translational applications [233]. Similarly, JHU083, another L-DON prodrug, not only disrupts tumor cell metabolic pathways and induces apoptosis, but also remodels the immunosuppressive tumor microenvironment by promoting T-cell proliferation and infiltration, reducing Tregs and inducing Th1-mediated immune responses [182, 234]. Glutamine uptake inhibitors Cancer cells exhibit heightened demand for glutamine, rendering the overexpression of glutamine transporters, including SLC1A5, SLC7A11, SLC38A1, SLC38A2, and SLC6A14, on the cellular membrane critical for their survival and proliferation. Indeed, upregulation of these transporters not only drives cancer cell growth but also serves as a clinical biomarker predictive of poor prognosis in patients with non-small cell lung cancer (NSCLC), prostate cancer, breast cancer, and acute myeloid leukemia (AML). While drug development targeting glutamine metabolism has achieved varying degrees of progress, glutamine transporter inhibition has shown the most promising therapeutic results in clinical trials [6]. SLC1A5 (ASCT2).SLC1A5 is a high-affinity glutamine transporter whose efficiency is significantly enhanced under acidic conditions, thereby providing sufficient substrates for tumor cells thriving in hypoxic tumor microenvironments. Previous studies first identified benzylserine as an inhibitor of SLC1A5 activity in breast cancer cells, but this drug exhibits non-specificity [235]. Currently, V-9302 serves as a potent competitive small-molecule antagonist specifically targeting SLC1A5. Its actions contain inhibition of tumor cell growth and proliferation, induction of oxidative stress and subsequent cell death [236]. To enhance tumor-specific targeting and therapeutic efficacy, multiple optimized drug delivery strategies have been explored. In breast cancer models, the co-assembly of the photosensitizer pyropheophorbide a (PPa) with V-9302 into PPa/V-9302 nanoparticles (NPs) demonstrate dual therapeutic advantages: enhanced tumor-targeted drug accumulation and potent suppression of in vivo tumor progression [237]. Besides, L-γ-glutamyl-p-nitroanilide has been validated as another SLC1A5 inhibitor, demonstrating dose-dependent inhibition of tumor cells viability and proliferation, and inducing apoptosis [238, 239]. SLC1A5 (ASCT2). SLC1A5 is a high-affinity glutamine transporter whose efficiency is significantly enhanced under acidic conditions, thereby providing sufficient substrates for tumor cells thriving in hypoxic tumor microenvironments. Previous studies first identified benzylserine as an inhibitor of SLC1A5 activity in breast cancer cells, but this drug exhibits non-specificity [235]. Currently, V-9302 serves as a potent competitive small-molecule antagonist specifically targeting SLC1A5. Its actions contain inhibition of tumor cell growth and proliferation, induction of oxidative stress and subsequent cell death [236]. To enhance tumor-specific targeting and therapeutic efficacy, multiple optimized drug delivery strategies have been explored. In breast cancer models, the co-assembly of the photosensitizer pyropheophorbide a (PPa) with V-9302 into PPa/V-9302 nanoparticles (NPs) demonstrate dual therapeutic advantages: enhanced tumor-targeted drug accumulation and potent suppression of in vivo tumor progression [237]. Besides, L-γ-glutamyl-p-nitroanilide has been validated as another SLC1A5 inhibitor, demonstrating dose-dependent inhibition of tumor cells viability and proliferation, and inducing apoptosis [238, 239]. SLC7A11.The cystine/glutamate antiporter SLC7A11 plays a crucial role within cells not only by facilitating cystine uptake that is essential for GSH biosynthesis, but also by determining the cell’s reliance on glutamine metabolism. Given the high expression of SLC7A11 in various types of tumors, targeting SLC7A11 for intervention is considered a promising therapeutic strategy. Notably, combining drugs that target SLC7A11 with those targeting glutaminolysis is expected to further enhance therapeutic efficacy [25]. Recently, several SLC7A11 inhibitors have been identified, including Erastin, IKE (Imidazole ketone erastin), Sulfasalazine, Sorafenib, and HG106 [240]. Erastin is a classic ferroptosis inducer, and glutamine-dependent tumor cells exhibit high sensitivity to it, leading to tumor growth inhibition through inducing ferroptosis [241]. However, the low solubility of Erastin limits its in vivo bioavailability, prompting the development of novel derivatives such as IKE and Piperazine erastin. These derivatives have demonstrated significant antitumor activity against diffuse large B-cell lymphoma and fibromas [242].Given that the development time of IKE is relatively short, it has not yet entered the clinical trial stage. In contrast, Sorafenib and Sulfasalazine, both FDA-approved drugs, have already been widely utilized in clinical practice. Sulfasalazine can inhibit the proliferation of glutamine-depleted TNBC (triple-negative breast cancer) cells both in vitro and in vivo, and demonstrates therapeutic potential against a variety of tumors, including lymphoma, lung cancer, and prostate cancer [243]. Clinical studies have also revealed that Sulfasalazine can reduce GSH levels in CD44-positive tumor stem cells in some patients with advanced gastric cancer; however, its dosing regimen and patient tolerability still require in-depth clinical validation [244]. Sorafenib can induce ferroptosis by inhibiting SLC7A11, thereby impeding tumor growth, and has currently been approved for the treatment of RCC (renal cell carcinoma), HCC, and thyroid cancer [245, 246]. Furthermore, the combinatorial administration of Sorafenib with other agents (including Regorafenib, Pioglitazone, and Orlistat) has been shown to significantly amplify ferroptosis induction, resulting in a synergistic enhancement of antitumor efficacy [247, 248].Notably, cancer cells with high SLC7A11 expression typically rely on glutamine to achieve glutamate-derived anaplerosis. This metabolic vulnerability provides a theoretical basis for the development of therapeutic agents targeting SLC7A11-high cancer cells. For example, the glutaminase inhibitor CB-839 exhibits significantly stronger inhibitory effects on the growth of xenograft tumors derived from Keap1-mutant cells or patients with aberrant SLC7A11 expression, compared to its effects on Keap1 wild-type cells [249]. Moreover, SLC7A11high cancer cells exhibit greater susceptibility to cell death induced by GLUT inhibitors [118]. Therefore, by formulating targeted glutamine metabolism inhibition strategies based on the unique gene mutation characteristics or relevant expression patterns of each tumor patient, we are enabled to provide robust support for precision tumor therapy. SLC7A11. The cystine/glutamate antiporter SLC7A11 plays a crucial role within cells not only by facilitating cystine uptake that is essential for GSH biosynthesis, but also by determining the cell’s reliance on glutamine metabolism. Given the high expression of SLC7A11 in various types of tumors, targeting SLC7A11 for intervention is considered a promising therapeutic strategy. Notably, combining drugs that target SLC7A11 with those targeting glutaminolysis is expected to further enhance therapeutic efficacy [25]. Recently, several SLC7A11 inhibitors have been identified, including Erastin, IKE (Imidazole ketone erastin), Sulfasalazine, Sorafenib, and HG106 [240]. Erastin is a classic ferroptosis inducer, and glutamine-dependent tumor cells exhibit high sensitivity to it, leading to tumor growth inhibition through inducing ferroptosis [241]. However, the low solubility of Erastin limits its in vivo bioavailability, prompting the development of novel derivatives such as IKE and Piperazine erastin. These derivatives have demonstrated significant antitumor activity against diffuse large B-cell lymphoma and fibromas [242]. Given that the development time of IKE is relatively short, it has not yet entered the clinical trial stage. In contrast, Sorafenib and Sulfasalazine, both FDA-approved drugs, have already been widely utilized in clinical practice. Sulfasalazine can inhibit the proliferation of glutamine-depleted TNBC (triple-negative breast cancer) cells both in vitro and in vivo, and demonstrates therapeutic potential against a variety of tumors, including lymphoma, lung cancer, and prostate cancer [243]. Clinical studies have also revealed that Sulfasalazine can reduce GSH levels in CD44-positive tumor stem cells in some patients with advanced gastric cancer; however, its dosing regimen and patient tolerability still require in-depth clinical validation [244]. Sorafenib can induce ferroptosis by inhibiting SLC7A11, thereby impeding tumor growth, and has currently been approved for the treatment of RCC (renal cell carcinoma), HCC, and thyroid cancer [245, 246]. Furthermore, the combinatorial administration of Sorafenib with other agents (including Regorafenib, Pioglitazone, and Orlistat) has been shown to significantly amplify ferroptosis induction, resulting in a synergistic enhancement of antitumor efficacy [247, 248]. Notably, cancer cells with high SLC7A11 expression typically rely on glutamine to achieve glutamate-derived anaplerosis. This metabolic vulnerability provides a theoretical basis for the development of therapeutic agents targeting SLC7A11-high cancer cells. For example, the glutaminase inhibitor CB-839 exhibits significantly stronger inhibitory effects on the growth of xenograft tumors derived from Keap1-mutant cells or patients with aberrant SLC7A11 expression, compared to its effects on Keap1 wild-type cells [249]. Moreover, SLC7A11high cancer cells exhibit greater susceptibility to cell death induced by GLUT inhibitors [118]. Therefore, by formulating targeted glutamine metabolism inhibition strategies based on the unique gene mutation characteristics or relevant expression patterns of each tumor patient, we are enabled to provide robust support for precision tumor therapy. SLC38A1 (SNAT1) and SLC38A2 (SNAT2).Both SLC38A1 and SLC38A2 can drive glutamine influx and are closely associated with various types of cancers, including melanoma, breast cancer, gastric cancer, osteosarcoma, endometrial cancer, prostate cancer, and liver cancer. The tyrosine kinase inhibitor Gilteritinib has been approved for the treatment of relapsed/refractory AML patients with FLT3 mutations. Studies have found that SLC38A1 is a novel target of Gilteritinib, which promotes cellular senescence by reducing ATP generation and GSH synthesis [250]. Another SLC38A1/A2 inhibitor, α-(methylamino) isobutyric acid (MeAIB), has also been demonstrated to slow down cancer cells’ growth, migration, and invasion, and induce senescence in melanoma cells [251]. SLC38A1 (SNAT1) and SLC38A2 (SNAT2). Both SLC38A1 and SLC38A2 can drive glutamine influx and are closely associated with various types of cancers, including melanoma, breast cancer, gastric cancer, osteosarcoma, endometrial cancer, prostate cancer, and liver cancer. The tyrosine kinase inhibitor Gilteritinib has been approved for the treatment of relapsed/refractory AML patients with FLT3 mutations. Studies have found that SLC38A1 is a novel target of Gilteritinib, which promotes cellular senescence by reducing ATP generation and GSH synthesis [250]. Another SLC38A1/A2 inhibitor, α-(methylamino) isobutyric acid (MeAIB), has also been demonstrated to slow down cancer cells’ growth, migration, and invasion, and induce senescence in melanoma cells [251]. SLC7A5 (LAT1).The amino acid transporter SLC7A5 mediates transmembrane glutamine transport, and its high-affinity inhibitor JPH203 (KYT0353) has advanced to Phase I clinical trials. In patients with advanced solid malignancies, this agent has demonstrated promising therapeutic efficacy along with favorable tolerability and safety profiles [252]. SLC7A5 (LAT1). The amino acid transporter SLC7A5 mediates transmembrane glutamine transport, and its high-affinity inhibitor JPH203 (KYT0353) has advanced to Phase I clinical trials. In patients with advanced solid malignancies, this agent has demonstrated promising therapeutic efficacy along with favorable tolerability and safety profiles [252]. Glutamine catabolic-related enzymes inhibitors GLS is the first rate-limiting enzyme in glutamine metabolism. At present, numerous anticancer agents targeting GLS have been developed that show promising therapeutic potential. In 2014, it was first reported that the GLS inhibitor CB-839 (Telaglenastat) exhibited potent antitumor activity. Preclinical studies demonstrated that CB-839 effectively suppressed TNBC, myeloproliferative neoplasms (MPNs), AML, gastric cancer, RCC, ovarian cancer, and colorectal cancer [253–258]. It is worth noting that CB-839 has now entered the clinical trial stage. Interestingly, combination therapy with CB-839 and the JAK1/2 inhibitor ruxolitinib or the glycolytic inhibitor 3PO demonstrated enhanced efficacy, suggesting potential synergistic effects through concurrent targeting of distinct metabolic or oncogenic pathways [259]. However, a study has elucidated that in STK11/Lkb1-deficient lung cancer, the combined use of CB-839 negatively impacts anti-PD1 immunotherapy. This adverse effect arises because CD8 T cell activation and cytotoxicity are critically dependent on glutamate availability [260]. This may be associated with the fact that STK11 mutations lead to decreased PD-L1 expression and reduced immune infiltration. Furthermore, this is also related to the augmented glutamine dependency and constrained compensatory capacity of T cells in the TME. Another GLS inhibitor, BPTES (Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide), has been demonstrated to exert antitumor effects both in vitro and in vivo, inhibiting distant tumor growth and metastasis while increasing the abundance of memory T cells to enhance immune responses [188, 261, 262]. As previously mentioned, researchers have developed a BPTES-loaded biomimetic copper-doped polypyrrole nanoparticle nanosystem that effectively induces cuproptosis in breast cancer cells [142]. Furthermore, co-delivery of BPTES and cisplatin (CDDP) can prevent cisplatin efflux by reducing GSH and ATP production, thereby promoting cisplatin-induced DNA damage, blocking the mTOR signaling pathway, and facilitating apoptosis. Hence, this approach significantly enhances the sensitivity of ovarian cancer cells to cisplatin [263]. As mentioned above, CuP can not only induce cuproptosis in tumor cells but also elevate the levels of IFN-γ and TNF-α, increase the number of CD8 + T cells, and transform a cold tumor microenvironment into a hot one [142]. Besides, Compound 968 (5-(3-bromo-4-(dimethylamino)phenyl)-2,2-dimethyl-2,3,5,6-tetrahydrobenzo [a]phenanthridin-4(1H)-one, C968) is also an allosteric inhibitor of GLS that enhances the ability of CD8+ T cells to induce apoptosis in ovarian cancer cells and promotes the secretion of CXCL10 and CXCL11 by tumor cells [264]. Furthermore, combination therapy with C968 and anti-PD-L1 agents has been shown to potentiate anti-ovarian cancer immune responses [264]. In addition, a study has reported that C968 and its derivative SY-1320 can overcome Adriamycin resistance in human MCF-7ADR cells, providing a novel combination therapeutic strategy to address drug resistance in breast cancer patients [265]. Moreover, self-assembly of C968 with the photosensitizer Ce6 enhances photodynamic therapy efficacy by depleting GSH levels, leading to severe apoptosis and increased immunogenicity of tumor cells [266]. In addition, other GLS inhibitors including CPD-3B and EGCG have also demonstrated promising antitumor activity. Notably, HYL001 exhibits dual mechanisms of action: it not only suppresses GLS expression but also triggers apoptosis in cancer stem cells through inhibition of the mitochondrial TCA cycle [267]. However, most of these agents remain in preclinical phase and have not yet been approved for clinical application. Moreover, inhibitors targeting other enzymes involved in glutamine metabolism also exhibit antitumor effects. GLUD1 inhibitor R162 suppresses in vitro proliferation of lung cancer cells by inducing redox imbalance and attenuates tumor cells growth and metastatic potential in vivo [268, 269]. Furthermore, the aminotransferase inhibitor aminooxyacetate (AOA) primarily mediates cell death through the endoplasmic reticulum stress pathway, holding potential value for treating c-Myc overexpressing breast cancer patients with glutamine addiction [270]. However, as a broad-spectrum transaminase inhibitor, AOA also targets PSAT1, thereby inhibiting tumor metastasis [271]. Limitation of glutamine-targeting drugs and combination therapy strategies Although numerous in vitro studies indicate that targeting glutamine metabolism can inhibit the development of various cancers, its clinical application still faces many challenges. Tumor cells can evade the effects of glutamine inhibitors through multiple mechanisms. First, besides glucose and glutamine, tumor cells can utilize lipids and acetate for energy [5]. When glutamine metabolism is blocked, glutamine-dependent cells generate oxaloacetate through pathways like pyruvate carboxylase and glycolysis to maintain the TCA cycle functions [284]. Second, in response to glutamine depletion, p53 upregulates SLC1A3 and SLC7A3, promoting glutamine synthesis or using alternative amino acids for cell survival [285, 286]. Macropinocytosis also helps maintain amino acid levels. Ras-transformed and KRAS-mutant cells can take up extracellular proteins via macropinocytosis to escape glutamine-dependent growth [287]. Glutamine deficiency can also selectively activate the EGFR-Pak signaling pathway, which then initiates macropinocytosis to cope with nutrient scarcity in the TME [288]. Notably, macropinocytosis is closely related to aspartate metabolism, and their synergy can alleviate growth inhibition caused by glutamine deficiency [289]. Furthermore, the systemic toxicity is a major obstacle for glutamine-targeted therapies. Since normal cells also rely on glutamine, these therapies may cause unintended side effects. Therefore, in the future, we need to further study and clarify the nutrient utilization characteristics of tumor cells in vivo and overcome metabolic plasticity through multi-target interventions, such as simultaneously blocking multiple metabolic pathways, inhibiting amino acid transporters, or macropinocytosis. This may be an effective therapeutic strategy to address resistance to glutamine inhibitors. Combination therapy, a potent way to tackle tumor heterogeneity, holds great promise in cancer treatment. Due to the limitations of glutamine inhibitors, combining them with drugs targeting other compensatory pathways or cellular functions can effectively address these issues [290]. Clinical research has demonstrated that appropriate glutamine supplementation in cancer patients not only enhances their clinical status and mitigates the risks linked to high-dose chemotherapy and radiotherapy but also does not promote tumor growth. Interestingly, chemotherapeutic drugs work better in a low-glutamine metabolic environment [291]. For example, combining glutamine metabolism inhibitors (e.g., CB-839, BPTES) with platinum drugs, paclitaxel, or pemetrexed can significantly boost anti-tumor effects [292]. Additionally, studies have revealed that radiotherapy-resistant tumor cells show reduced activity in glycolysis, the TCA cycle, and mitochondrial respiration but increased glutamine metabolism. Based on this, reducing glutamine synthetase is an effective way to enhance cancer cell radiosensitivity, delay DNA repair, and inhibit nucleotide metabolism [293]. In targeted therapy, synergistic delivery of V-9302 and the histone deacetylase inhibitor MS-275 (HDACi, also named Entinostat) via nanocarriers induces robust ROS accumulation and pyroptosis in uveal melanoma (UVM), thereby promoting the infiltration of DC cells, NK cells and CTLs and effectively inhibiting tumor progression [294]. Similarly, Sorafenib combined with other agents (Regorafenib, Pioglitazone, and Orlistat) has been shown to significantly amplify ferroptosis induction, thereby synergistically enhancing antitumor efficacy and prolonging survival outcomes [247, 248]. Additionally, KRas-dependent tumors often upregulate glutamine metabolism to resist mTORC1 inhibition, and the co-administration of CB-839 can markedly overcome this resistance [295]. Moreover, CB-839 combined with the JAK1/2 inhibitor ruxolitinib or the glycolysis inhibitor 3PO shows better efficacy, indicating potential synergies in targeting different metabolic/oncogenic pathways [259]. Therefore, clinicians need to develop personalized treatment plans based on each patient’s unique metabolic profile. Currently, the combination therapy of glutamine inhibitors and immune checkpoint blockade antibodies shows great promise [296]. In ARID1A-inactivated ovarian cancer models, co-using CB-839 and anti-PD-L1 significantly curbs tumor growth [297]. In ovarian cancer models, C968 enhances the ability of CD8+ T cells to induce tumor cell apoptosis and secrete chemokines CXCL10 and CXCL11. Combining C968 with anti-PD-L1 further enhances the anti-tumor immune response in a synergistic way [264]. Similarly, a PD-L1 monoclonal antibody combined with JHU-083 broadly inhibits tumor cell metabolism, raises glutamine and glucose levels in the tumor microenvironment (TME), and improves treatment results compared to monotherapy [220, 292, 293]. Also, BPTES plus PD-L1 can mitigate metabolic compensation-driven glycolysis and PD-L1 upregulation-induced immune escape from single glutamine inhibition [298]. Moreover, BVC loaded with chlorin e6, V9302, and PD1/PDL1 blockers (BMS-1) reprograms glutamine metabolism, enhances immune recognition, and prevents immune escape to treat metastatic tumors [299]. However, the combination of glutamine inhibitors and PD-1 therapy also faces challenges in clinical translation. As mentioned above, in an STK11-/Lkb1-deficient lung cancer model, the combined use of CB-839 weakens the efficacy of PD-1 immunotherapy [260]. This highlights the need to selectively block cancer cell glutamine uptake in the TME while supplying glutamine to immune cells. Conclusions and perspectives With the deepening of the research on the mechanisms of cell death, we have gained a clearer understanding of the inextricable link between cell metabolism and cell death. The unique metabolic characteristics of tumor cells endow them with inherent vulnerabilities, providing a potential breakthrough for cancer therapy. Currently, ferroptosis, cuproptosis, and disulfidptosis have been uniformly categorized as a type of metabolic cell death [300]. These forms of cell death are triggered by different metabolic perturbations, further underscoring the importance of metabolism in cell death. In the nutrient-deprived TME, glutamine plays a crucial role in ensuring the survival of tumor cells. Given this, glutamine metabolism has emerged as an attractive target in the field of cancer therapy. In this review, we have provided an overview of the complex associations between different cell death forms and glutamine metabolism. However, it is important to note that the interplay between cell death and glutamine metabolism is highly intricate, and the threshold at which glutamine promotes or inhibits cell death remains unclear. Furthermore, the complex communication among various cell types within the TME further complicates cancer treatment. A critical direction for future research is to figure out how to specifically deprive tumor cells of glutamine supply while ensuring adequate nutritional support for anti-tumor immune cells. Based on tumor cell-specific antigens, developing nanocarriers that can precisely deliver glutamine metabolism inhibitors to tumor cells while minimizing impacts on normal cells has become a research trend in future cancer therapy. Targeting glutamine metabolism exhibits strong anti-tumor potential by obstructing cellular energy supply, inducing oxidative stress, and activating immune responses. At present, some reviews have summarized the efficacy and mechanisms of action of glutamine metabolism-related anti-cancer drugs [295]. Although the use of glutamine metabolism inhibitors represents a promising therapeutic approach, tumor cells can still cleverly evade their effects through various strategies. For instance, tumor cells can enhance their metabolic flexibility, take up extracellular amino acids via compensatory transporters and macropinocytosis, while expressing nutrient stress-response proteins in response to nutrient deprivation [301]. Moreover, the heterogeneity of tumor cells, activation of compensatory pathways, and immunosuppressive effects are all prone to leading to drug resistance in tumor cells. Although the combined use of inhibitors targeting compensatory pathways or immune checkpoint inhibitors may enhance the killing effect of drugs on cancer cells [174], this strategy requires further clinical research to validate its effectiveness. Given the multiple functions of glutamine, the development of drugs targeting glutamine metabolism still faces numerous challenges. With the rapid development of artificial intelligence technology, analyzing the three-dimensional structures of enzymes in glutamine metabolism from a structural biology perspective and identifying the key amino acid residues involved in glutamine recognition and binding can facilitate the design and optimization of targeted inhibitors, providing new opportunities for the treatment of various cancers. In tumor cells with KRAS mutations, TP53, KEAP1, and STK11/Lkb1 endow tumor cells with unique metabolic environments and phenotypic characteristics. These unique features subsequently give rise to significantly disparate therapeutic responses when a single drug is administered. Consequently, by making use of these characteristics, we can use glutamine metabolism inhibitors in a flexible and personalized way, which helps achieve more effective precision treatment. Overall, although targeting glutamine metabolism holds great promise for cancer therapy, numerous uncertainties and challenges still lie ahead. Acknowledgements The schematic diagrams presented in this review were created using BioGDP (https://biogdp.com) [302]. Abbreviations α-Ketoglutarate Acute myeloid leukemia Adenosine monophosphate Aminooxyacetate Asparagine synthetase Atypical memory B cells Bcl-2 associated athanogene 3 Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl) ethyl sulfide IL-10-expressing regulatory B cells Dendritic cells Cisplatin Chronic myeloid leukemia Cytidine triphosphate Damage-associated molecular patterns Death-inducing signaling complex 6-Diazo-5-oxo-L-norleucine Endotoxin tolerance Ferredoxin 1 Iron-sulfur cluster proteins Glutamate-cysteine ligase Glutaminase Glutamate Glutamate dehydrogenase Guanosine monophosphate Glutamic-oxaloacetic transaminase Glucose oxidase Glutamic pyruvate transaminase Glutamine synthetase Glutathione Glutathione synthetase Oxidized glutathione Hepatocellular carcinoma Neck squamous cell carcinoma Inosine monophosphate Jumonji C domain Lipoyl synthase S-adenosylmethionine synthetase Malate dehydrogenase 1 Myeloid-derived suppressor cells Malic enzyme 1 Mitochondrial membrane potential N-acetyl-aspartyl-glutamate Nonessential amino acid Neutrophil extracellular traps Natural killer cells Nuclear factor erythroid 2-related factor 2 Non-small cell lung cancer Oxaloacetate Renal cell carcinoma Pancreatic ductal adenocarcinoma Phosphoserine aminotransferase Regulated cell death Retinal ganglion cells Serine/threonine-protein kinase 1 Reactive oxygen species Radiation therapy S-adenosylmethionine Serine hydroxymethyltransferase Solute carrier family 1 member 5 Solute carrier family 3 member 2 Solute carrier family 6 member 14 Solute carrier family 7 member 11 Solute carrier family 38 member 2 & 5 Tert-butyl hydroperoxide Tricarboxylic acid Effector T cell Ten-eleven-translocation Follicular helper T cells Tumor microenvironment Triple-negative breast cancer Regulatory T cells Unc51-like kinase 1 Uridine triphosphate Author contributions XP conceived the ideals, designed the figures, and wrote and revised the manuscript. YT and SL contributed significantly to the critical revision and improvement of the manuscript. All authors participate in the conceptualization and development of the manuscript, and approved the final published version. Funding This work was supported by: Hunan Provincial Key Area R&D Programs 2021SK2013 (YT). National Natural Science Foundation of China 82073097 (SL). The Science and Technology Innovation Program of Hunan Province 2022RC3072 (YT). Fundamental Research Funds for the Central Universities of Central South University 2024ZZTS0148 (XP). Hunan Provincial Innovation Foundation for Postgraduate CX20240288 (XP). Data availability No datasets were generated or analysed during the current study. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Shuang Liu, Email: shuangliu2016@csu.edu.cn. Yongguang Tao, Email: taoyong@csu.edu.cn. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.